TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2967-2984

  Harati, K ^a   Chromik, A M ^b   Bulut, D ^b   Goertz, O ^a   Hahn, S ^c   Hirsch, T ^a   Klein Hitpass, L ^d   Lehnhardt, M ^a   Uhl, W ^b   Daigeler, A ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Apoptosis; CDKN1B; Chemotherapy; CSF2; Doxorubicin; DUSP1; FACS; FADD; Fibrosarcoma; GADD45B; Gene expression; HT1080; JUNB; Mafosfamide; Necrosis; NFKBIA; NOS1; Proliferation; SOCS3; SOD2; Soft tissue sarcoma; Synergism; Taurolidine; TNFAIP3; Trabectedin; TRAIL

Indexed keywords

BROXURIDINE; CASPASE; COLONY STIMULATING FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; I KAPPA B KINASE ALPHA; MAFOSFAMIDE; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NEURONAL NITRIC OXIDE SYNTHASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TAUROLIDINE; TRABECTEDIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C JUN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SARCOMA CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DIOXOLES; DOXORUBICIN; DRUG SYNERGISM; FIBROSARCOMA; HUMANS; RECOMBINANT PROTEINS; TAURINE; TETRAHYDROISOQUINOLINES; THIADIAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84865700867     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57(1): 43-66, 2007.
2. Fernebro J, Bladstrom A, Rydholm A, Gustafson P, Olsson H, Engellau J and Nilbert M: Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients. Br J Cancer 95(8): 986-990, 2006.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54(1): 8-29, 2004.
4. Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF and Singer S: Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 15(11): 1667-1672, 2004.
5. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350(9092): 1647-1654, 1997.
6. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM and Brennan MF: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85(2): 389-395, 1999.
7. Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J and Hajdu SI: The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 214(3): 328-336; discussion 336-328, 1991.
8. Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS and Romsdahl MM: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 211(4): 476-481, 1990.
9. Donato Di Paola E and Nielsen OS: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4): S138-141, 2002.
10. Nedea EA and DeLaney TF: Sarcoma and skin radiation oncology. Hematol Oncol Clin North Am 20(2): 401-429, 2006.
11. Brodowicz T, Schwameis E, Widder J, Amann G, Wiltschke C, Dominkus M, Windhager R, Ritschl P, Potter R, Kotz R, Zielinski CC: Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma 4(4): 151-160, 2000.
12. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D and Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19(5): 1238-1247, 2001.
13. Kaushal A and Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am 88(3): 629-646, viii, 2008.
14. Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD and Lev D: TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 16(9): 2591-2604, 2010.
15. Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B: Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer 9: 87, 2010.
16. Komdeur R, Meijer C, Van Zweeden M, De Jong S, Wesseling J, Hoekstra HJ, van der Graaf WT: Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol 25(3): 677-684, 2004.
17. Kang J, Bu J, Hao Y, Chen F: Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis 8(3): 274-279, 2005.
18. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94(8): 2836-2843, 1999.
19. Jacob E, Scorsone K, Blaney SM, D'Argenio DZ, Berg SL: Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer 50(4): 757-760, 2008.
20. Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkotter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg 20 (6): 339-348, 2007.
21. Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein- Hitpass L, Mittelkotter U, Uhl W, Chromik AM: TRAIL and taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res 27: 82, 2008.
22. Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkotter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol 32(6): 1205-1220, 2008.
23. Srivastava RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3(6): 535-546, 2001.
24. McCourt M, Wang JH, Sookhai S and Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo . Ann Surg Oncol 7 (9): 685-691, 2000.
25. Jacobi CA, Menenakos C and Braumann C: Taurolidine-a new drug with antitumor and antiangiogenic effects. Anticancer Drugs 16(9): 917-921, 2005.
26. Braumann C, Winkler G, Rogalla P, Menenakos C and Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 4: 34, 2006.
27. Wang Z, Watt W, Brooks NA, Harris MS, Urban J, Boatman D, McMillan M, Kahn M, Heinrikson RL, Finzel BC, Wittwer AJ, Blinn J, Kamtekar S and Tomasselli AG: Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors. Biochim Biophys Acta 1804 (9): 1817-1831, 2010.
28. Schrantz N, Blanchard DA, Auffredou MT, Sharma S, Leca G and Vazquez A: Role of caspases and possible involvement of retinoblastoma protein during TGFbeta-mediated apoptosis of human B lymphocytes. Oncogene 18(23): 3511-3519, 1999.
29. Backes C, Keller A, Kuentzer J, Kneissl B, Comtesse N, Elnakady YA, Muller R, Meese E, Lenhof HP: GeneTrail-advanced gene set enrichment analysis. Nucleic Acids Res 35(Web Server issue): W186-192, 2007.
30. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1): 27-30, 2000.
31. Krull M, Voss N, Choi C, Pistor S, Potapov A, Wingender E: TRANSPATH: an integrated database on signal transduction and a tool for array analysis. Nucleic Acids Res 31(1): 97-100, 2003.
32. Barrett T, Edgar R: Mining microarray data at NCBI's Gene Expression Omnibus (GEO)&z.ast;. Methods Mol Biol 338: 175-190, 2006.
33. Scurr M, Judson I: Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas. Hematol Oncol Clin North Am 19(3): 489-500, vi, 2005.
34. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4(8): 1977-1983, 1998.
35. Cassier PA, Duret A, Tredan O, Carrabin N, Meeus P, Treilleux I, Guastalla JP, Ray-Coquard I: New developments in treatment of ovarian carcinoma: focus on trabectedin. Cancer Manag Res 2: 233-242, 2010.
36. Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Vigano L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L: Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 45(7): 1153-1161, 2009.
37. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y, Jimeno J, Faircloth G, Bertino JR: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7 (9): 2908-2911, 2001.
38. Grivas A, Trafalis DT, Thanopoulou E, Ziras NG, Athanasiou AE: Treatment with trabectedin: Should be indicated for all soft tissue sarcoma histotypes? J BUON 15(4): 791-793, 2010.
39. Gajdos C and Elias A: Trabectedin: safety and efficacy in the treatment of advanced sarcoma. Clin Med Insights Oncol 5: 35-43, 2011.
40. Thornton KA: Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Core Evid 4: 191-198, 2010.
41. Epperly MW, Gretton JE, Sikora CA, Jefferson M, Bernarding M, Nie S and Greenberger JS: Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiat Res 160(5): 568-578, 2003.
42. Guo G, Yan-Sanders Y, Lyn-Cook BD, Wang T, Tamae D, Ogi J, Khaletskiy A, Li Z, Weydert C, Longmate JA, Huang TT, Spitz DR, Oberley LW and Li JJ: Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol 23(7): 2362-2378, 2003.
43. Greenberger JS and Epperly MW: Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo 21(2): 141-146, 2007.
44. Murley JS, Kataoka Y, Cao D, Li JJ, Oberley LW and Grdina DJ: Delayed radioprotection by NFkappaB-mediated induction of SOD2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs. Radiat Res 162(5): 536-546, 2004.
45. Epperly MW, Epstein CJ, Travis EL and Greenberger JS: Decreased pulmonary radiation resistance of manganese superoxide dismutase (MnSOD)-deficient mice is corrected by human manganese superoxide dismutase-plasmid/liposome (SOD2-PL) intratracheal gene therapy. Radiat Res 154(4): 365-374, 2000.
46. Murley JS, Nantajit D, Baker KL, Kataoka Y, Li JJ and Grdina DJ: Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine. Radiat Res 169(5): 495-505, 2008.
47. Qu Y, Zhao S, Hong J and Tang S: Radiosensitive gene therapy through imRNA expression for silencing manganese superoxide dismutase. J Cancer Res Clin Oncol 136(6): 953-959, 2010.
48. Sharifi N, Hurt EM, Thomas SB, Farrar WL: Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. Clin Cancer Res 14(19): 6073-6080, 2008.
49. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B and Scheidereit C: Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed- Sternberg cells. Blood 97(9): 2798-2807, 2001.
50. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr. and Sledge GW Jr.: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17(7): 3629-3639, 1997.
51. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5(1): 119-127, 1999.
52. Wang CY, Mayo MW and Baldwin AS Jr.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274(5288): 784-787, 1996.
53. Li J, Minnich DJ, Camp ER, Brank A, Mackay SL and Hochwald SN: Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. J Surg Res 132(1): 112-120, 2006.
54. Park JM, Kim A, Oh JH and Chung AS: Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis 28(4): 837-847, 2007.
55. Park HJ, Chung HJ, Min HY, Park EJ, Hong JY, Kim WB, Kim SH and Lee SK: Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochem Pharmacol 71(1-2): 21-31, 2005.
56. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, Arai H, Tsuruo T and Fujita N: PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res 7(4): 557-569, 2009.
57. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T and Debatin KM: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 91(12): 4624-4631, 1998.
58. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L, Mattii L, Battolla B, Capodanno A, Collecchi P, Veroni F, Simi P, Piaggi S, Casini A and Petrini M: PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 32(1): 103-112, 2008.
59. Ludwig H, Khayat D, Giaccone G and Facon T: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104(9): 1794-1807, 2005.
60. Sitko JC, Yeh B, Kim M, Zhou H, Takaesu G, Yoshimura A, McBride WH, Jewett A, Jamieson CA and Cacalano NA: SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal 20(12): 2221-2230, 2008.
61. Yasukawa H, Sasaki A and Yoshimura A: Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18: 143- 164, 2000.
62. Shouda T, Hiraoka K, Komiya S, Hamada T, Zenmyo M, Iwasaki H, Isayama T, Fukushima N, Nagata K and Yoshimura A: Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Lett 231(2): 176-184, 2006.
63. Li N, Grivennikov SI and Karin M: The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19(4): 429-431, 2011.
64. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB and Tweardy DJ: STAT3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule STAT3 inhibitor. Blood 117 (21): 5701-5709, 2011.
65. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D and Weissenberger J: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 101(3): 393-403, 2011.
66. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL and Gao AC: RNA interference targeting STAT3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60(4): 303-309, 2004.
67. Rebbaa A, Chou PM and Mirkin BL: Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 7(6): 393-400, 2001.
68. Mesa RA: Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 13 (6): 394-403, 2010.
69. Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, Kowolik C, Xin H, Chen L, Kretzner L, Yu H, Wilcox WR, Yen Y, Forman S and Jove R: The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25(3): 538-550, 2011.
70. Yang SH, Khadka DB, Cho SH, Ju HK, Lee KY, Han HJ, Lee KT and Cho WJ: Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. Bioorg Med Chem 19(2): 968-977, 2011.
71. Vairapandi M, Balliet AG, Hoffman B and Liebermann DA: GADD45b and GADD45g are CDC2/cyclinB1 kinase inhibitors with a role in S and G-2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol 192 (3): 327-338, 2002.
72. Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE and Lev D: Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent upregulation of GADD45 alpha. Cancer Res 68(8): 2895-2903, 2008.
73. Zenmyo M, Tanimoto A, Sakakima H, Yokouchi M, Nagano S, Yamamoto T, Ishido Y, Komiya S and Ijiri K: GADD45beta expression in chondrosarcoma: a pilot study for diagnostic and biological implications in histological grading. Diagn Pathol 5: 69, 2010.
74. Owens DM and Keyse SM: Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26(22): 3203-3213, 2007.
75. Lang R, Hammer M and Mages J: DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 177(11): 7497-7504, 2006.
76. Bodart JF, Chopra A, Liang X and Duesbery N: Anthrax, MEK and cancer. Cell Cycle 1(1): 10-15, 2002.
77. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19(56): 6594-6599, 2000.
78. Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH and Duesbery NS: Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 7(3): 648-658, 2008.
79. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M and Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res 22(2A): 809-814, 2002.
80. Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y and Frei K: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 5(2): 194-210, 2009.
81. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U and Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma-a mouse model. J Surg Res 143 (2): 372-378, 2007.
82. Sun BS, Wang JH, Liu LL, Gong SL and Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol 96(3): 241-248, 2007.
83. Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W and Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 56(3): 327-336, 2007.
84. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L and Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J 34(6): 1399-1407, 2009.
85. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W and Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 24(2C): 1143-1147, 2004.
86. Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Mohler H and Bigler L: Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI- MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinet 46(6): 513-524, 2007.
87. Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8(10): 782-798, 2008.
88. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T and Anderson KC: TRAIL/APO2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98 (3): 795-804, 2001.
89. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL and Czuczman MS: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 103(12): 1783-1787, 2010.
90. Westermarck J, Lohi J, Keski-Oja J and Kahari VM: Okadaic acid-elicited transcriptional activation of collagenase gene expression in HT-1080 fibrosarcoma cells is mediated by JunB. Cell Growth Differ 5(11): 1205-1213, 1994.
91. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, Daino L, Simile MM, De Miglio MR, Virdis P, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F and Pascale RM: Dualspecificity phosphatase 1 ubiquitination in extracellular signalregulated kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res 68(11): 4192-4200, 2008.
92. Keyse SM and Emslie EA: Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359(6396): 644-647, 1992.
93. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB andXu J: A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 64(6): 1997-1999, 2004.
94. Gebauer S, Yu AL, Omura-Minamisawa M, Batova A and Diccianni MB: Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma. Genes Chromosomes Cancer 41(4): 297-308, 2004.
95. Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman MC and Spitz DR: Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response. Int J Radiat Oncol Biol Phys 73 (3): 886-896, 2009.
96. Kiningham KK, Cardozo ZA, Cook C, Cole MP, Stewart JC, Tassone M, Coleman MC and Spitz DR: All-trans-retinoic acid induces manganese superoxide dismutase in human neuroblastoma through NF-kappaB. Free Radic Biol Med 44 (8): 1610-1616, 2008.
97. Nakagawa SA, Lopes A, Lopes de Carvalho A, Rossi BM, Werneck da Cunha I, Soares FA, Chung WT and Alves LA: Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92(8): 1738-1746, 2010.
98. Chen CN, Hsieh FJ, Cheng YM, Chang KJ and Lee PH: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. J Surg Oncol 94(3): 226-233, 2006.
99. Campbell KJ, O'Shea JM and Perkins ND: Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors. BMC Cancer 6: 101, 2006.
100. Hu Q, Zhou MX, Liu SY, Zhang LQ, Liu AQ, Guo YJ and Song Y: Regulation of NF-kappaB/P65 by MDM2 in acute lymphoblastic leukemia in childhood. Chin J Pediatrics 41(12): 921-924, 2003.
101. Song HY, Rothe M and Goeddel DV: The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci USA 93(13): 6721-6725, 1996.
102. Collins SA, Buhles A, Scallan MF, Harrison PT, O'Hanlon DM, O'Sullivan GC and Tangney M: AAV2-mediated in vivo immune gene therapy of solid tumours. Genet Vaccines Ther 8: 8, 2010.
103. Huttinger C, Hirschberger J, Jahnke A, Kostlin R, Brill T, Plank C, Kuchenhoff H, Krieger S and Schillinger U: Neoadjuvant gene delivery of feline granulocyte-macrophage colony-stimulating factor using magnetofection for the treatment of feline fibrosarcomas: a phase I trial. J Gene Med 10(6): 655-667, 2008.
104. Casey G, Cashman JP, Morrissey D, Whelan MC, Larkin JO, Soden DM, Tangney M and O'Sullivan GC: Sonoporation mediated immunogene therapy of solid tumors. Ultrasound Med Biol 36(3): 430-440, 2010.
105. Thomas LR, Johnson RL, Reed JC and Thorburn A: The Cterminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FAS receptors have opposing functions in FAS-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem 279(50): 52479-52486, 2004.
106. Thomas LR, Henson A, Reed JC, Salsbury FR and Thorburn A: Direct binding of FAS-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem 279(31): 32780-32785, 2004.